B2M mutation paves the way for immune tolerance in pathogenesis of Epstein-Barr virus positive diffuse large B-cell lymphomas

This study focused genetic pathogenesis and tumor microenvironment of Epstein-Barr virus (EBV) positive diffuse large B-cell lymphomas (DLBCL) in patients without immunodeficiency. DNA samples from these cases were sequenced by next generation sequencing (NGS) using a selected gene panel. Results revealed that most gene mutations were not specific for EBV positive DLBCL. However, B2M (β2-microglobulin) mutations were significantly increased and HLA-I or HLA-II expression was decreased in these cases, which was related to patient's poor outcome. B2M mutations and deregulation of B2M expression were further confirmed by Sanger sequencing and immunohistochemistry. Reducing the infiltration of CD8+ T lymphocytes, related to decreased expression of HLA-I or HLA-II was found in these patients. These results suggest that the mutations of B2M could cause the disruption of the expression and functions of this important subunit of HLA, leading to decreased expression of HLA-I or HLA-II and subsequently to reduce T lymphocyte infiltration in tumor tissues. The consequence of this event lessens the recognition and elimination of EBV+ tumor cells by host immunity and paves the way for the host immune tolerance to EBV+ tumor cells by evading immune recognition and escaping the T lymphocyte killing.

[1]  H. Holte,et al.  Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. , 2020, Haematologica.

[2]  J. Castillo,et al.  EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[3]  Andrew J. Dunford,et al.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. , 2019, Blood advances.

[4]  A. López-Guillermo,et al.  Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death‐ligand 1 (PD‐L1) axis in post‐transplant lymphoproliferative disorders: association with Epstein–Barr virus, PD‐L1 copy number alterations, and outcome , 2019, Histopathology.

[5]  A. Salar,et al.  New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO) , 2019, British journal of haematology.

[6]  K. Gu,et al.  Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count , 2019, BMC Cancer.

[7]  A. Tzankov,et al.  Lymphomas and Their Microenvironment: A Multifaceted Relationship , 2019, Pathobiology.

[8]  Nguyen Phuoc Long,et al.  Comprehensive Multi-Omics Analysis Reveals Aberrant Metabolism of Epstein–Barr-Virus-Associated Gastric Carcinoma , 2019, Cells.

[9]  A. Rickinson,et al.  The Global Landscape of EBV-Associated Tumors , 2019, Front. Oncol..

[10]  Wei Liu,et al.  Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes , 2019, Front. Oncol..

[11]  A. Gill,et al.  The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma , 2019, European journal of haematology.

[12]  X. Jiang,et al.  EPSTEIN–BARR VIRUS‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA FEATURES DISRUPTED ANTIGEN CAPTURE/PRESENTATION AND HIJACKED T‐CELL SUPPRESSION , 2019, Hematological Oncology.

[13]  Byeong-Bae Park,et al.  Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma , 2019, International journal of molecular sciences.

[14]  L. Weiss,et al.  Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update. , 2018, Human pathology.

[15]  W. Yin,et al.  Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma , 2018, PloS one.

[16]  K. Young,et al.  EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk‐stratification and management , 2018, American journal of hematology.

[17]  I. Voutsadakis.  Polymerase epsilon mutations and concomitant β2-microglobulin mutations in cancer. , 2018, Gene.

[18]  M. Kloor,et al.  High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer , 2018, Oncoimmunology.

[19]  J. Cerhan,et al.  Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression , 2017, Haematologica.

[20]  Kwok Wai Lo,et al.  Epstein–Barr virus infection and nasopharyngeal carcinoma , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.

[21]  M. Narbaitz,et al.  Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact , 2017, Scientific Reports.

[22]  E. Noguchi,et al.  Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer , 2017, Cancer Chemotherapy and Pharmacology.

[23]  A. Baranova,et al.  Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions , 2017, Journal of Translational Medicine.

[24]  J. H. Park,et al.  Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era , 2016, Oncotarget.

[25]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[26]  M. Taguri,et al.  Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy. , 2015, Leukemia research.

[27]  S. Steinberg,et al.  EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. , 2015, Blood.

[28]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[29]  Y. Ko.  EBV and human cancer , 2015, Experimental & Molecular Medicine.

[30]  K. Young,et al.  EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management , 2015, Experimental & Molecular Medicine.

[31]  W. Klapper,et al.  Detection of EBV in reactive and neoplastic lymphoproliferations in adults—when and how? , 2014, Journal of Hematopathology.

[32]  W. Choi,et al.  Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries , 2014, Clinical Cancer Research.

[33]  S. Pittaluga.  Viral-associated lymphoid proliferations. , 2013, Seminars in diagnostic pathology.

[34]  E. Jaffe,et al.  Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. , 2011, Blood.

[35]  P. Cresswell,et al.  Regulation of MHC class I assembly and peptide binding. , 2008, Annual review of cell and developmental biology.

[36]  J. Weissenbach,et al.  The beta2‐microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. , 1983, The EMBO journal.

[37]  Sonali M. Smith,et al.  Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.